Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Longevity
D-retro-inverso senolytic peptide — selectively kills senescent cells via FOXO4-p53 disruption.
Peptide B
Longevity
Central cellular cofactor — supplemented to support mitochondrial function and sirtuin activity.
Typical vial
10 mg
Typical dose
Per kg dosing (research) mcg
Half-life
Extended via DRI backbone (~hours-days)
FDA status
Not FDA approved. In preclinical / early clinical developmen…
Typical vial
500 mg
Typical dose
50-200 mg (SubQ); 500-1500 mg (IV) mcg
Half-life
~6-10 hours (cellular turnover)
FDA status
Not FDA approved as a therapeutic. Available via compounding…
FOX04-DRI effects
NAD+ (Injectable) effects
FOX04-DRI side effects
NAD+ (Injectable) side effects
FOX04-DRI dosing ranges
Senolytic research (research-only)
0.4-5 mg/kg · Every other day for 1-2 weeks per cycle · Cycle-based per protocol
NAD+ (Injectable) dosing ranges
IV anti-aging clinic protocol
500-1500 mg · Per infusion, weekly to monthly · Cycle-based
Subcutaneous wellness
50-200 mg · Daily or alternate-day · 2-4 week cycles
Intranasal
20-100 mg · Daily · Cycle-based
FOX04-DRI: D-retro-inverso senolytic peptide — selectively kills senescent cells via FOXO4-p53 disruption. Typical dose Per kg dosing (research) mcg. NAD+ (Injectable): Central cellular cofactor — supplemented to support mitochondrial function and sirtuin activity. Typical dose 50-200 mg (SubQ); 500-1500 mg (IV) mcg. Both fall under the Longevity category.
Stacking FOX04-DRI with NAD+ (Injectable) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
FOX04-DRI is typically dosed: Every other day for 1-2 weeks per cycle for Senolytic research (research-only). NAD+ (Injectable) is typically dosed: Per infusion, weekly to monthly for IV anti-aging clinic protocol; Daily or alternate-day for Subcutaneous wellness; Daily for Intranasal.
FOX04-DRI: Not FDA approved. In preclinical / early clinical development as Proxofim (Cleara Biotech). NAD+ (Injectable): Not FDA approved as a therapeutic. Available via compounding pharmacies for off-label use. NAD+ precursors (NR as Niagen, NMN) sold as dietary supplements.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free